INVA News - Candlesense

Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

WALTHAM, Mass.--(BUSINESS WIRE)--Prix Galien Award 2025

How might this award influence the company's R&D pipeline perception and future pipeline development? Could this award nomination affect the company’s ability to raise capital or financing terms? Is there any expected change in trading volume or volatility following the announcement?

Awards

11 days ago

Read more businesswire

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectio...

What risks or uncertainties were highlighted that could influence Innoviva's future performance? Were there any significant one‑time items or non‑recurring expenses that investors should adjust for when evaluating the results? What impact might the reported results have on the stock's short‑term price movement and trading volume?

Earnings

18 days ago

Read more businesswire

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Pa...

Clinical trials

2 months ago

Read more businesswire

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Pa...

Clinical trials

2 months ago

Read more businesswire

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

WALTHAM, Mass. & GENEVA, Switzerland--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & D...

Clinical trials

3 months ago

Read more businesswire